BRPI0511897A - método para tratar distúrbios de glándula sebácea hiperativa, e, uso de uma composição fotossensibilizadora hidrofóbica e/ou lipofìlica - Google Patents
método para tratar distúrbios de glándula sebácea hiperativa, e, uso de uma composição fotossensibilizadora hidrofóbica e/ou lipofìlicaInfo
- Publication number
- BRPI0511897A BRPI0511897A BRPI0511897-2A BRPI0511897A BRPI0511897A BR PI0511897 A BRPI0511897 A BR PI0511897A BR PI0511897 A BRPI0511897 A BR PI0511897A BR PI0511897 A BRPI0511897 A BR PI0511897A
- Authority
- BR
- Brazil
- Prior art keywords
- hydrophobic
- lipophilic
- gland disorders
- sebaceous gland
- photosensitizing composition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000003504 photosensitizing agent Substances 0.000 title abstract 3
- 230000002209 hydrophobic effect Effects 0.000 title abstract 2
- 230000002165 photosensitisation Effects 0.000 title abstract 2
- 208000015390 Sebaceous gland disease Diseases 0.000 title 1
- 210000004907 gland Anatomy 0.000 abstract 2
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- ALSTYHKOOCGGFT-UHFFFAOYSA-N cis-oleyl alcohol Natural products CCCCCCCCC=CCCCCCCCCO ALSTYHKOOCGGFT-UHFFFAOYSA-N 0.000 abstract 1
- 231100000223 dermal penetration Toxicity 0.000 abstract 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- -1 lemuteporphine Chemical class 0.000 abstract 1
- 238000002428 photodynamic therapy Methods 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- 150000004032 porphyrins Chemical class 0.000 abstract 1
- 238000011200 topical administration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0076—PDT with expanded (metallo)porphyrins, i.e. having more than 20 ring atoms, e.g. texaphyrins, sapphyrins, hexaphyrins, pentaphyrins, porphocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
MéTODO PARA TRATAR DISTúRBIOS DE GLáNDULA SEBáCEA HIPERATIVA, E, USO DE UMA COMPOSIçãO FOTOSSENSIBILIZADORA HIDROFóBICA E/OU LIPOFìLICA O presente método envolve o tratamento fotodinâmico de distúrbios de glândula hiperativa. O método envolve a administração tópica de uma composição fotossensibilizadora compreendendo porfirinas verdes hidrofóbicas e/ou lipofilicas tais como lemuteporfina, polietileno glicol e realçadores da penetração dérmica tais como álcool oleílico e TRANSCUTOL<32> para afetar a pele e a exposição subseqüente desta pele à energia de um comprimento de onda capaz de ativar o fotossensibilizador.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002470403A CA2470403A1 (en) | 2004-02-06 | 2004-06-09 | Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders |
PCT/CA2005/000154 WO2005120572A1 (en) | 2004-06-09 | 2005-02-08 | Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied hydrophobic green porphyrins |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0511897A true BRPI0511897A (pt) | 2008-01-15 |
Family
ID=37649609
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0511897-2A BRPI0511897A (pt) | 2004-06-09 | 2005-02-08 | método para tratar distúrbios de glándula sebácea hiperativa, e, uso de uma composição fotossensibilizadora hidrofóbica e/ou lipofìlica |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP1755676B1 (pt) |
JP (1) | JP2008501727A (pt) |
AU (1) | AU2005251395A1 (pt) |
BR (1) | BRPI0511897A (pt) |
CA (1) | CA2568744A1 (pt) |
DK (1) | DK1755676T3 (pt) |
ES (1) | ES2400566T3 (pt) |
MX (1) | MX2007000338A (pt) |
NZ (1) | NZ551636A (pt) |
WO (1) | WO2005120572A1 (pt) |
ZA (1) | ZA200610239B (pt) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2454974T3 (es) | 2007-06-27 | 2014-04-14 | The General Hospital Corporation | Aparato para la inhibición óptica de la terapia fotodinámica |
US8492578B2 (en) * | 2007-12-14 | 2013-07-23 | Photoderma Sa | Compounds useful in therapeutic and cosmetic methods |
WO2009093144A2 (en) * | 2008-01-25 | 2009-07-30 | Qlt, Inc.Lau | Photodynamic therapy of sebaceous gland disorders |
FR2927800A1 (fr) * | 2008-02-25 | 2009-08-28 | Oreal | Association d'un rayonnement lumineux et d'un compose bioconvertible par la lipase pour ameliorer l'apparence de la peau et/ou du cheveu. |
WO2010071230A1 (ja) | 2008-12-17 | 2010-06-24 | 学校法人慶應義塾 | 細胞特異的能動集積性を有する光線力学療法剤 |
AU2012205410A1 (en) * | 2011-01-13 | 2013-08-01 | Qlt Inc. | Pharmaceutical compositions for topical delivery of photosensitizers and uses thereof |
EP2794004B1 (en) * | 2011-12-19 | 2020-07-29 | Photocure ASA | Irradiation apparatus |
HU230989B1 (hu) * | 2013-01-17 | 2019-08-28 | Gd Photonics Kft. | Készítmény az UVB-fényterápia hatékonyságának fokozására, eljárás annak előállítására és alkalmazása |
CN105899201A (zh) * | 2013-12-20 | 2016-08-24 | 盖尔德马研究及发展公司 | 光损伤的皮肤的脉冲光动力治疗 |
US10603508B2 (en) | 2015-10-15 | 2020-03-31 | Dusa Pharmaceuticals, Inc. | Adjustable illuminators and methods for photodynamic therapy and diagnosis |
WO2017197104A1 (en) * | 2016-05-11 | 2017-11-16 | The Jackson Laboratory | Yap1 inhibitors and methods |
FR3109086A1 (fr) | 2020-04-14 | 2021-10-15 | Ifremer | utilisation d’un extrait polaire de Skeletonema dans une thérapie photodynamique |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5171749A (en) | 1987-01-20 | 1992-12-15 | University Of British Columbia | Wavelength-specific cytotoxic agents |
US5095030A (en) | 1987-01-20 | 1992-03-10 | University Of British Columbia | Wavelength-specific cytotoxic agents |
GB8805849D0 (en) | 1988-03-11 | 1988-04-13 | Efamol Holdings | Porphyrins & cancer treatment |
US5955490A (en) | 1989-07-28 | 1999-09-21 | Queen's University At Kingston | Photochemotherapeutic method using 5-aminolevulinic acid and other precursors of endogenous porphyrins |
US6492420B2 (en) * | 1995-03-10 | 2002-12-10 | Photocure As | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
IL116126A0 (en) | 1995-11-24 | 1996-01-31 | Yeda Res & Dev | Process for the preparation of bacteriochlorophyllis some novel compounds of this type and pharmaceutical compositions comprising them |
US6004821A (en) | 1998-03-07 | 1999-12-21 | Levine; Robert A. | Method and apparatus for performing chemical, qualitative, quantitative, and semi-quantitative analyses of a urine sample |
AU4645099A (en) | 1998-07-09 | 2000-02-01 | Yoram Harth | Apparatus and method for efficient high energy photodynamic therapy of acne vulgaris and seborrhea |
US6887260B1 (en) * | 1998-11-30 | 2005-05-03 | Light Bioscience, Llc | Method and apparatus for acne treatment |
US6183773B1 (en) * | 1999-01-04 | 2001-02-06 | The General Hospital Corporation | Targeting of sebaceous follicles as a treatment of sebaceous gland disorders |
IL133253A0 (en) | 1999-12-01 | 2001-04-30 | Yeda Res & Dev | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them |
GB0005855D0 (en) | 2000-03-10 | 2000-05-03 | Scotia Holdings Plc | Compounds for pdt |
GB2370992B (en) | 2000-03-23 | 2002-11-20 | Photo Therapeutics Ltd | Therapeutic light source and method |
GB2361430A (en) | 2000-04-17 | 2001-10-24 | Photo Therapeutics Ltd | Therapeutic discharge lamps |
WO2002013788A1 (en) | 2000-08-16 | 2002-02-21 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Topical aminolevulinic acid-photodynamic therapy for acne vulgaris |
US6984395B2 (en) * | 2001-04-11 | 2006-01-10 | Qlt, Inc. | Drug delivery system for hydrophobic drugs |
US7018396B2 (en) * | 2001-08-07 | 2006-03-28 | New England Medical Center Hospitals, Inc. | Method of treating acne |
BR0214004A (pt) * | 2001-11-09 | 2004-11-03 | Quadra Logic Tech Inc | Composição, uso da mesma, métodos de tratamento de alopecia androgenética, cânceres da pele, acne, ou para promover o crescimento dos pêlos, e de terapia fotodinâmica, e, processo da fabricação de uma composição |
AU2003230808A1 (en) * | 2002-04-05 | 2003-10-27 | Candela Corporation | High fluence rate activation of photosensitizers for dermatological applications |
CA2457214A1 (en) * | 2004-02-06 | 2005-08-06 | Qlt Inc. | Photodynamic therapy for the treatment of acne |
-
2005
- 2005-02-08 ES ES05714425T patent/ES2400566T3/es active Active
- 2005-02-08 NZ NZ551636A patent/NZ551636A/en not_active IP Right Cessation
- 2005-02-08 BR BRPI0511897-2A patent/BRPI0511897A/pt not_active IP Right Cessation
- 2005-02-08 EP EP05714425A patent/EP1755676B1/en not_active Not-in-force
- 2005-02-08 WO PCT/CA2005/000154 patent/WO2005120572A1/en active Application Filing
- 2005-02-08 JP JP2007526135A patent/JP2008501727A/ja active Pending
- 2005-02-08 DK DK05714425.5T patent/DK1755676T3/da active
- 2005-02-08 CA CA002568744A patent/CA2568744A1/en not_active Abandoned
- 2005-02-08 MX MX2007000338A patent/MX2007000338A/es active IP Right Grant
- 2005-02-08 AU AU2005251395A patent/AU2005251395A1/en not_active Abandoned
-
2006
- 2006-12-06 ZA ZA200610239A patent/ZA200610239B/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK1755676T3 (da) | 2013-02-18 |
EP1755676B1 (en) | 2012-11-28 |
NZ551636A (en) | 2009-12-24 |
ZA200610239B (en) | 2008-06-25 |
JP2008501727A (ja) | 2008-01-24 |
EP1755676A1 (en) | 2007-02-28 |
WO2005120572A1 (en) | 2005-12-22 |
EP1755676A4 (en) | 2010-12-22 |
ES2400566T3 (es) | 2013-04-10 |
CA2568744A1 (en) | 2005-12-22 |
AU2005251395A1 (en) | 2005-12-22 |
MX2007000338A (es) | 2007-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0511897A (pt) | método para tratar distúrbios de glándula sebácea hiperativa, e, uso de uma composição fotossensibilizadora hidrofóbica e/ou lipofìlica | |
BRPI0507406A (pt) | método de tratamento de acne vulgaris, e, uso de um fotossensibilizante de porfirina verde e solubilizador | |
Lawrence et al. | The UV/visible radiation boundary region (385–405 nm) damages skin cells and induces “dark” cyclobutane pyrimidine dimers in human skin in vivo | |
Darlenski et al. | Photodynamic therapy in dermatology: past, present, and future | |
Lee et al. | Fractional laser as a tool to enhance the skin permeation of 5-aminolevulinic acid with minimal skin disruption: a comparison with conventional erbium: YAG laser | |
Forster et al. | Penetration enhancement of two topical 5‐aminolaevulinic acid formulations for photodynamic therapy by erbium: YAG laser ablation of the stratum corneum: continuous versus fractional ablation | |
Lopez et al. | Enhanced Delivery of 5‐Aminolevulinic Acid Esters by Iontophoresis In Vitro¶ | |
Fluhr et al. | In vivo skin treatment with tissue‐tolerable plasma influences skin physiology and antioxidant profile in human stratum corneum | |
Haedersdal et al. | Enhanced uptake and photoactivation of topical methyl aminolevulinate after fractional CO2 laser pretreatment | |
Genina et al. | Low-intensity indocyanine-green laser phototherapy of acne vulgaris: pilot study | |
Angelo et al. | Chemical and physical strategies in onychomycosis topical treatment: A review | |
Issa et al. | Topical delivery of triamcinolone via skin pretreated with ablative radiofrequency: a new method in hypertrophic scar treatment | |
JP6933685B2 (ja) | 光損傷皮膚のパルス光力学的処置 | |
FR2924021B1 (fr) | Composition pour le traitement de la peau par therapie photodynamique | |
Cho et al. | Therapeutic efficacy and safety of a 1927-nm fractionated thulium laser on pattern hair loss: an evaluator-blinded, split-scalp study | |
Serrano et al. | Microneedling dilates the follicular infundibulum and increases transfollicular absorption of liposomal sepia melanin | |
BR0213996A (pt) | Método e aparelho para estimular o crescimento capilar | |
WO2000040266A3 (en) | Targeting of sebaceous follicles as a treatment of sebaceous gland disorders | |
Gupta et al. | Medical devices for the treatment of onychomycosis | |
WO2000028971A1 (de) | 5-aminolävulinsäure-nanoemulsion | |
Samy et al. | Effect of methylene blue-mediated photodynamic therapy for treatment of basal cell carcinoma | |
Rhee et al. | Effect of low-level laser treatment on cochlea hair-cell recovery after acute acoustic trauma | |
JP2024050723A (ja) | 皮膚障害に対する光線力学的治療方法 | |
Huang et al. | Transdermal delivery of three vitamin C derivatives by Er: YAG and carbon dioxide laser pretreatment | |
Shan et al. | An open uncontrolled trial of topical 5-aminolevulinic acid photodynamic therapy for the treatment of urethral condylomata acuminata in male patients |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: dismissal - article 86 of industrial property law |
Free format text: REFERENTE A 7A ANUIDADE. |
|
B08K | Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87) |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |